Reply by Authors
J Urol
.
2021 May;205(5):1359-1360.
doi: 10.1097/JU.0000000000001547.03.
Epub 2021 Mar 11.
Authors
Nitin K Yerram
1
,
Lori Long
2
,
Luke P O'Connor
1
,
Alex Z Wang
1
,
Michael Ahdoot
1
,
Amir H Lebastchi
1
,
Sandeep Gurram
1
,
Johnathan Zeng
3
,
Heather Chalfin
1
,
Stephanie A Harmon
4
,
Sherif Mehralivand
5
,
Maria J Merino
6
,
Howard L Parnes
6
,
Peter L Choyke
5
,
Joanna Shih
7
,
Bradford J Wood
2
,
Baris Turkbey
5
,
Peter A Pinto
1
Affiliations
1
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
2
Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
3
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
4
Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland.
5
Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
6
Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
7
Division of Cancer Prevention, National Cancer Institutes, National Institutes of Health, Bethesda, Maryland.
PMID:
33705228
DOI:
10.1097/JU.0000000000001547.03
No abstract available
Publication types
Comment